Immunic (IMUX) Change in Acquisitions & Divestments (2013 - 2023)

Immunic (IMUX) reported Change in Acquisitions & Divestments of $4.4 million for Q2 2023, down 19.89% sequentially from $5.4 million in Q1 2023.

Immunic (IMUX) Change in Acquisitions & Divestments (2013 - 2023) Analysis & Trends

Immunic (IMUX) has 2 years of Change in Acquisitions & Divestments data on file, last reported at $4.4 million in Q2 2023.

For the quarter ending Q2 2023, Change in Acquisitions & Divestments changed N/A year-over-year to $4.4 million; the trailing twelve-month figure through Jun 2023 stood at $9.8 million (up 95.88% YoY), and the FY2013 full-year result was $17.0 million, changed N/A from the prior year.
Change in Acquisitions & Divestments retreated to $4.4 million in Q2 2023, from $5.4 million in the prior quarter.
In the past five years, Change in Acquisitions & Divestments ranged from a high of $5.4 million in Q1 2023 to a low of $4.4 million in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,042.03 Bn	67,041.74 Bn	-
2	Nanobiotix	1,908.00 Bn	1,907.94 Bn	-
3	Akari Therapeutics	959.56 Bn	959.56 Bn	-
4	BeOne Medicines	472.89 Bn	468.10 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.12 Bn	114.87 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.04 Bn	61.29 Bn	3.31 Bn
7	Belite Bio	62.68 Bn	62.68 Bn	-
8	Argenx Se	55.90 Bn	50.72 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.47 Bn	34.46 Bn	959.66 Mn
10	Immunic	424.32 Mn	424.32 Mn	-

Download Data